T-bet is a transcription factor, one of the control proteins in the cell nucleus that can turn specific groups of genes on ...

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

Allogeneic cell therapies are advancing in clinical trials, requiring oncologists and pathologists to understand the ...

Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed ...

The UAB researchers showed that TREM2 — which stands for triggering receptors expressed on myeloid cells 2 — is predominantly ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...